11 citations
,
April 2018 in “Journal of Dermatology” Dutasteride safely treats hair loss without harming sexual function.
January 2017 in “Revista da Universidade Vale do Rio Verde” Finasteride is commonly used for male pattern hair loss but has potential risks, including irreversible sexual dysfunction.
1 citations
,
May 2025 in “The Journal of Rheumatology” Upadacitinib may help treat difficult cases of systemic lupus erythematosus.
May 2011 in “Psychiatric News” Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.
November 2013 in “Journal of clinical & experimental dermatology research” Dutasteride can help treat hair loss in both men and women.
February 2013 in “Journal of The American Academy of Dermatology” Using hair loss drugs finasteride and dutasteride may cause sexual side effects.
2 citations
,
March 2018 in “Current Opinion in Urology” 5-alpha reductase inhibitors can cause sexual, neurologic, endocrine, and cardiovascular side effects, but these are rare and usually stop after ending treatment.
Dutasteride is more effective and better tolerated than finasteride for hair loss treatment.
1 citations
,
July 2024 in “Journal of the European Academy of Dermatology and Venereology” Oral dutasteride is effective and safe for treating frontal fibrosing alopecia.
February 2025 in “Journal of the European Academy of Dermatology and Venereology” Oral dutasteride is a recommended first treatment for frontal fibrosing alopecia.
4 citations
,
September 2024 in “BMC Cancer” Adding dutasteride to therapy may improve treatment for advanced salivary duct cancer.
17 citations
,
December 2015 in “BMC Complementary and Alternative Medicine” A new plant extract from Avicennia marina could potentially be used to treat common hair loss.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib works better in adolescents than adults for treating severe alopecia areata.
1 citations
,
April 2023 in “Heliyon” Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.
4 citations
,
May 2019 in “Asian Journal of Pharmaceutical Sciences” Created tablet similar to Avodart using γ-cyclodextrin and solubilizers.
August 2025 in “Journal of the American Academy of Dermatology” April 2022 in “Reactions Weekly” 2 citations
,
April 2024 in “Journal of Clinical Psychopharmacology” Dutasteride helps reduce heavy drinking, especially for those who drink to cope.
27 citations
,
March 2017 in “Current Clinical Pharmacology” Dutasteride is becoming a popular hair loss treatment, proving more effective than finasteride with similar side effects.
August 2024 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.
November 2021 in “Revista Ibero-Americana de Humanidades, Ciências e Educação” The document does not give specific results for hair loss treatment effectiveness.
1 citations
,
April 2025 in “Tropical Journal of Natural Product Research” Avicennia marina shows potential to treat Hepatitis C by targeting key proteins.
September 2022 in “Journal of The American Academy of Dermatology” Combining dutasteride mesotherapy with oral minoxidil is more effective for hair loss than using oral minoxidil alone.
64 citations
,
June 2009 in “Journal of The American Academy of Dermatology” Oral dutasteride can potentially treat frontal fibrosing alopecia in postmenopausal women, with some patients showing disease arrest and hair regrowth.
12 citations
,
July 2023 in “Journal of the European Academy of Dermatology and Venereology” Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.
March 2024 in “EMBO molecular medicine” Antiviral drugs, especially daclatasvir, may be a new treatment for a rare skin disease, improving survival and reducing symptoms in mice.
January 2017 in “The American Pharmacists Association eBooks”